Table 2.
The relationship between PGC mRNA expression and the clinicopathological characteristics of breast cancer
| Clinicopathological features | Variable | Low expression | High expression | P |
|---|---|---|---|---|
| Age, n (%) | ≦60 | 292 (27%) | 309 (28.5%) | 0.345 |
| > 60 | 249 (23%) | 233 (21.5%) | ||
| T stage, n (%) | T1 | 137 (12.7%) | 140 (13%) | 0.537 |
| T2 | 321 (29.7%) | 308 (28.5%) | ||
| T3 | 62 (5.7%) | 77 (7.1%) | ||
| T4 | 19 (1.8%) | 16 (1.5%) | ||
| N stage, n (%) | N0 | 259 (24.3%) | 255 (24%) | 0.136 |
| N1 | 177 (16.6%) | 181 (17%) | ||
| N2 | 64 (6%) | 52 (4.9%) | ||
| N3 | 29 (2.7%) | 47 (4.4%) | ||
| M stage, n (%) | M0 | 456 (49.5%) | 446 (48.4%) | 0.111 |
| M1 | 6 (0.7%) | 14 (1.5%) | ||
| Pathologic stage, n (%) | Stage I | 91 (8.6%) | 90 (8.5%) | 0.304 |
| Stage II | 311 (29.3%) | 308 (29.1%) | ||
| Stage III | 118 (11.1%) | 124 (11.7%) | ||
| Stage IV | 5 (0.5%) | 13 (1.2%) | ||
| Histological type, n (%) | IDC | 417 (42.7%) | 355 (36.3%) | < 0.001 |
| ILC | 71 (7.3%) | 134 (13.7%) | ||
| PR status, n (%) | Negative | 200 (19.3%) | 142 (13.7%) | < 0.001 |
| Indeterminate | 2 (0.2%) | 2 (0.2%) | ||
| Positive | 313 (30.3%) | 375 (36.3%) | ||
| ER status, n (%) | Negative | 146 (14.1%) | 94 (9.1%) | < 0.001 |
| Indeterminate | 2 (0.2%) | 0 (0%) | ||
| Positive | 367 (35.5%) | 426 (41.2%) | ||
| HER2 status, n (%) | Negative | 286 (39.3%) | 272 (37.4%) | 0.843 |
| Indeterminate | 7 (1%) | 5 (0.7%) | ||
| Positive | 83 (11.4%) | 74 (10.2%) | ||
| PAM50, n (%) | Normal | 16 (1.5%) | 24 (2.2%) | < 0.001 |
| Luminal A | 244 (22.5%) | 318 (29.4%) | ||
| Luminal B | 108 (10%) | 96 (8.9%) | ||
| Her2 + | 32 (3%) | 50 (4.6%) | ||
| Basal | 141 (13%) | 54 (5%) |
ILC Invasive lobular carcinoma, IDC Invasive ductal carcinoma, ER Estrogen receptor, PR Progesterone receptor